靶向SLAMF7的溶瘤腺病毒展现抗骨髓瘤疗效
研究评估了SLAMF7启动子驱动的溶瘤腺病毒Ad[CE1A]对多发性骨髓瘤的治疗潜力。Ad[CE1A]在骨髓瘤细胞系(n=8)、患者离体样本(n=17)中高效感染、复制并诱导溶瘤,对对照细胞系和健康供者(n=14)无此效应。体内实验显示Ad[CE1A]较载体对照显著降低骨髓瘤肿瘤负荷,与硼替佐米、美法仑、帕比司他、泊马度胺联用可增强疗效。
要点
- Ad[CE1A]在骨髓瘤细胞和患者样本中选择性感染、复制并诱导溶瘤。
- Ad[CE1A]诱导的细胞死亡不依赖caspase,可能涉及坏死性凋亡。
- Ad[CE1A]与美法仑等抗骨髓瘤药物联用可增强疗效。
核心结论
- 研究结果支持Ad[CE1A]作为有前景的骨髓瘤治疗手段。
研究设计与样本
- 在骨髓瘤细胞系(n=8)、骨髓瘤患者离体样本(n=17)和健康供者(n=14)中评估Ad[CE1A]的感染、复制和溶瘤作用。
- 采用5TGM1同系和U266异种移植模型进行体内实验,比较Ad[CE1A]与载体对照的肿瘤负荷。
- 联合抗骨髓瘤药物硼替佐米、美法仑、帕比司他、泊马度胺评估疗效增强作用。
主要发现
- Ad[CE1A]在骨髓瘤细胞中高效感染、复制并诱导溶瘤,而在对照细胞系或健康供者中无此效应,显示选择性细胞毒性。
- 机制研究显示Ad[CE1A]诱导的细胞死亡不依赖caspase,可能涉及坏死性凋亡。
- Ad[CE1A]改变免疫原性细胞死亡标志物(钙网蛋白、CD47、细胞外ATP),通过增加MHC I类和II类受体表达(HLA-ABC和HLA-DR)增强抗原呈递,并刺激旁观者细胞因子杀伤。
- 体内实验显示Ad[CE1A]较载体对照显著降低骨髓瘤肿瘤负荷。
- 与硼替佐米、美法仑、帕比司他、泊马度胺联用增强Ad[CE1A]疗效,其中美法仑上调SLAMF7导致病毒复制增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated a novel SLAMF7-promoter driven oncolytic adenovirus (Ad[CE1A]) as a potential therapeutic for multiple myeloma, an incurable hematological malignancy. Ad[CE1A] infection, replication, and oncolysis were assessed in a panel of myeloma cell lines (n = 8) and ex vivo samples from myeloma patients (n = 17) and healthy donors (HDs) (n = 14). Ad[CE1A] efficiently infected, replicated, and induced oncolysis in myeloma cells, but not in control cell lines or HDs, demonstrating selective cytotoxicity. Mechanistic studies revealed Ad[CE1A]-induced cell death is caspase-independent, with a potential involvement of necroptosis. Ad[CE1A] also altered immunogenic cell death markers (calreticulin, CD47, extracellular ATP), enhanced antigen presentation via increased MHC class I and II receptor expression (HLA-ABC and HLA-DR), and stimulated bystander cytokine killing, indicating potential for direct and immune-mediated anti-myeloma responses. In vivo experiments with 5TGM1 syngeneic and U266 xenograft models showed Ad[CE1A] significantly reduced myeloma tumor burden compared to vehicle control. Combination therapy with anti-myeloma drugs, bortezomib, melphalan, panobinostat and pomalidomide, enhanced Ad[CE1A] efficacy, with melphalan upregulating SLAMF7, resulting in increased viral replication. In summary, these findings support Ad[CE1A] as a promising myeloma therapy.
引用
- Stewart G, Tazzyman S, Sun Y, et al. An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy. Leukemia. 2025. PMID: 40247106. doi:10.1038/s41375-025-02617-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。